Aridis Pharmaceuticals

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARDS and other ETFs, options, and stocks.

About ARDS

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. 

CEO
Vu L. Truong
CEOVu L. Truong
Employees
34
Employees34
Headquarters
Los Gatos, California
HeadquartersLos Gatos, California
Founded
2003
Founded2003
Employees
34
Employees34

ARDS Key Statistics

Market cap
13.86M
Market cap13.86M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
4.65M
Average volume4.65M
High today
High today
Low today
Low today
Open price
$0.6701
Open price$0.6701
Volume
5.33K
Volume5.33K
52 Week high
$2.94
52 Week high$2.94
52 Week low
$0.5722
52 Week low$0.5722

ARDS News

Yahoo Finance 7d
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia - Yahoo Finance

Aridis Pharmaceuticals, Inc. LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results f...

Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia - Yahoo Finance

ARDS Earnings

-$1.94
-$1.29
-$0.65
$0.00
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
per share
Estimated per share
Actual
Expected Mar 30, After Hours
ActualExpected Mar 30, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.